Publications

List Publications

Crystal structures of protein-bound cyclic peptides.
Malde A, Hill TA, Iyer A, Fairlie DP.

Chemical Reviews 2019,119, 9861−9914.

A novel long-range n to π* interaction secures the smallest known α-helix in water.
Hoang HN, Wu C, Hill TA, de Araujo AD, Bernhardt PV, Liu L, Fairlie DP.

Angew Chem Int Ed Engl 2019, doi: 10.1002/anie.201911277. 

Twists or Turns: stabilising alpha vs beta turns in tetrapeptides.
Hoang HN, Hill TA, Ruiz-Gómez G, Diness F, Mason JM, Wu C, Abbenante G, Shepherd NE, Fairlie DP.

Chemical Science 2019, doi.org/10.1039/C9SC04153B.

Mirror image pairs of cyclic hexapeptides have different oral bioavailabilities and metabolic stabilities.
Lohman RJ, Nielsen DS, Kok WM, Hoang HN, Hill TA, Fairlie DP.

Chemical Communications 2019, 55, 13362-13365.

Computer modelling and synthesis of deoxy and monohydroxy analogues of a ribitylaminouracil bacterial metabolite that potently activates human T cells.
Ler GJM, Xu W, Mak JYW, Liu L, Bernhardt PV, Fairlie DP.

Chemistry  2019, Sep 17. doi: 10.1002/chem.201903732.

Diverse MR1-restricted T cells in mice and humans.
Koay H-F, Gherardin NA, Xu C, Seneviratna R, Zhao Z, Chen Z, Fairlie DP, McCluskey J, Pellicci DG, Uldrich AP, Godfrey DI.

Nature Communications 2019, 10, 2243.

MAIT cells upregulate α4β7 in response to acute Simian Immunodeficiency Virus/Simian HIV infection but are resistant to peripheral depletion in pigtail macaques.
Juno JA, Wragg KM, Amarasena T, Meehan BS, Mak JYW, Liu L, Fairlie DP, McCluskey J, Eckle SBG, Kent SJ.

J Immunol. 2019, 202, 2105-2120. 

Picture:  ©JoshKellogPhotography

Inhibitors of class I histone deacetylases attenuate thioacetamide-induced liver fibrosis in mice by suppressing hepatic type 2 inflammation.
Loh Z, Fitzsimmons RL, Reid RC, Ramnath D, Clouston A, Gupta PK, Irvine KM, Powell EE, Schroder K, Stow JL, Sweet MJ, Fairlie DP, Iyer A.

Br J Pharmacol 2019,176, 3775-3790. 

Pharmacological inhibition of protease-activated receptor-2 reduces crescent formation in rat nephrotoxic serum nephritis.
Han Y, Tian L, Ma F, Tesch G, Vesey DA, Gobe GC, Lohman RJ, Morais C, Suen JY, Fairlie DP, Nikolic-Paterson DJ.

Clin Exp Pharmacol Physiol 201946, 456-464.

Oxazole-benzenesulfonamide derivatives inhibit HIV-1 reverse transcriptase interaction with cellular eEF1A and reduce viral replication.
Rawle DJ, Li D, Wu Z, Wang L, Choong M, Lor M, Reid RC, Fairlie DP, Harris J, Tachedjian G, Poulsen SA, Harrich D.

J Virol 2019, 93(12). e00239-19. 

Alpha synuclein structure and Parkinson’s disease - lessons and emerging principles.
Meade RM, Fairlie DP, Mason JM.

Molecular Neurodegeneration 2019, 14, 29. 

Structure-activity relationships of wollamide cyclic hexapeptides with activity against drug-resistant and Intracellular Mycobacterium tuberculosis.
Khalil ZG, Hill TA, De Leon Rodriguez LM, Lohman RJ, Hoang HN, Reiling N, Hillemann D, Brimble MA, Fairlie DP, Blumenthal A, Capon RJ.

Antimicrob Agents Chemother 2019, 63(3), e01773-18. doi: 10.1128/AAC.01773-18

Histone deacetylases 1 and 2 inhibition suppresses cytokine production and osteoclast bone resorption in vitro.
Algate K, Haynes D, Fitzsimmons T, Romeo O, Wagner F, Holson E, Reid R, Fairlie D, Bartold P, Cantley M.

J Cell Biochem 2019, doi: 10.1002/jcb.29137.

Recipient mucosal-associated invariant T cells control GVHD within the colon.
Varelias A, Bunting MD, Ormerod KL, Koyama M, Olver SD, Straube J, Kuns RD, Robb RJ, Henden AS, Cooper L, Lachner N, Gartlan KH, Lantz O, Kjer-Nielsen L, Mak JY, Fairlie DP, Clouston AD, McCluskey J, Rossjohn J, Lane SW, Hugenholtz P, Hill GR.

J Clin Invest 2018, 128, 1919-1936.

Complement C3a and C5a receptors promote GVHD by suppressing mitophagy in recipient dendritic cells.
Nguyen H, Kuril S, Bastian D, Kim J, Zhang M, Vaena SG, Dany M, Dai M, Heinrichs JL, Daenthanasanmak A, Iamsawat S, Schutt S, Fu J, Wu Y, Fairlie DP, Atkinson C, Ogretmen B, Tomlinson S, Yu XZ.

JCI Insight 2018, Dec 20;3(24). pii: 121697. 

Chemical Approaches To Modulating Complement-Mediated Diseases.
Iyer A, Xu W, Reid RC, Fairlie DP.

J Med Chem 2018, 61, 3253-3276.

Bicyclic helical peptides as dual inhibitors selective for Bcl2A1 and Mcl-1 proteins.
de Araujo AD, Lim J, Wu KC, Xiang Y, Good AC, Skerlj R, Fairlie DP.

J Med Chem 2018, 61, 2962-2972. 

MAIT cells protect against pulmonary Legionella longbeachae infection.
Wang H, D'Souza C, Lim XY, Kostenko L, Pediongco TJ, Eckle SBG, Meehan BS, Shi M, Wang N, Li S, Liu L, Mak JYW, Fairlie DP, Iwakura Y, Gunnersen JM, Stent AW, Godfrey DI, Rossjohn J, Westall GP, Kjer-Nielsen L, Strugnell RA, McCluskey J, Corbett AJ, Hinks

Nature Communications 2018, 9, 3350. 

Hepatic expression profiling identifies steatosis-independent and steatosis-driven advanced fibrosis genes.
Ramnath D, Irvine KM, Lukowski SW, Horsfall LU, Loh Z, Clouston AD, Patel PJ, Fagan KJ, Iyer A, Lampe G, Stow JL, Schroder K, Fairlie DP, Powell JE, Powell EE, Sweet MJ.

JCI Insight 2018, 3(14), pii: 120274. 

Lysine deacetylases and regulated glycolysis in macrophages.
Shakespear MR, Iyer A, Cheng CY, Das Gupta K, Singhal A, Fairlie DP, Sweet MJ.

Trends Immunol 2018, 39, 473-488.

Chemically diverse helix-constrained peptides using selenocysteine crosslinking.
Dantas de Araujo A, Perry SR, Fairlie DP.

Org Lett 2018, 20, 1453-1456. 

Mucosal-associated invariant T cells augment immunopathology and gastritis in chronic Helicobacter pylori Infection.
D'Souza C, Pediongco T, Wang H, Scheerlinck JY, Kostenko L, Esterbauer R, Stent AW, Eckle SBG, Meehan BS, Strugnell RA, Cao H, Liu L, Mak JYW, Lovrecz G, Lu L, Fairlie DP, Rossjohn J, McCluskey J, Every AL, Chen Z, Corbett AJ.

J Immunol 2018, 200, 1901-1916. 

Glucuronic acid as a helix-inducing linker in short peptides.
Wu C, Hoang HN, Liu L, Fairlie DP.

Chemical Communications 2018, 54, 2162-2165.

A potent antagonist of protease-activated receptor 2 that inhibits multiple signalling functions in human cancer cells.
Jiang Y, Yau MK, Lim J, Wu KC, Xu W, Suen JY, Fairlie DP.

J Pharmacol Exp Ther 2018, 364, 246-257.

Contiguous hydrophobic and charged surface patches in short helix-constrained peptides drive cell permeability.
Perry SR, Hill TA, de Araujo AD, Hoang HN, Fairlie DP.

Org Biomol Chem 2018, 16, 367-371.

Orally Absorbed Cyclic Peptides
Nielsen DS, Shepherd NE, Xu W, Lucke AJ, Stoermer MJ, Fairlie DP

Chemical Reviews 2017, 117, 8094-8128.  

Exploiting a novel conformational switch to control innate immunity mediated by complement protein C3a.
Lohman RJ, Hamidon JK, Reid RC, Rowley JA, Yau MK, Halili MA, Nielsen DS, Lim J, Wu KC, Loh Z, Do A, Suen JY, Iyer A, Fairlie DP.

Nature Communications 2017, 8, 351. 

Stabilising short-lived Schiff base derivatives of 5-aminouracils that activate mucosal-associated invariant T cells.
Mak JYW, Xu W, Reid RC, Corbett AJ, Meehan B, Wang H, Chen Z, Rossjohn J, McCluskey J, Liu L, Fairlie DP.

Nature Communications 2017, 8, 14599. 

Drugs and drug-like molecules can modulate the function of mucosal-associated invariant T cells.
Keller AN, Eckle SB, Xu W, Liu L, Hughes VA, Mak JY, Meehan BS, Pediongco T, Birkinshaw RW, Chen Z, Wang H, D'Souza C, Kjer-Nielsen L, Gherardin NA, Godfrey DI, Kostenko L, Corbett AJ, Purcell AW, Fairlie DP*, McCluskey J*, Rossjohn J*.

Nature Immunology 2017, 18, 402-411. 

Protease activated receptor 2 controls myelin development, resiliency and repair.
Yoon H, Radulovic M, Walters G, Paulsen AR, Drucker K, Starski P, Wu J, Fairlie DP, Scarisbrick IA.

Glia 2017, 65, 2070-2086. 

Quinazolinone derivatives as inhibitors of homologous recombinase RAD51.
Ward A, Dong L, Harris JM, Khanna KK, Al-Ejeh F, Fairlie DP, Wiegmans AP, Liu L.

Bioorg Med Chem Lett 2017, 27, 3096-3100.

Europium-Labeled Synthetic C3a Protein as a Novel Fluorescent Probe for Human Complement C3a Receptor
Dantas de Araujo A, Wu C, Wu KC, Reid RC, Durek T, Lim J, Fairlie DP.

Bioconjug Chem 201728, 1669-1676.

The Ribosomal Protein S19 Suppresses Antitumor Immune Responses via the Complement C5a Receptor 1.
Markiewski MM, Vadrevu SK, Sharma SK, Chintala NK, Ghouse S, Cho JH, Fairlie DP, Paterson Y, Astrinidis A, Karbowniczek M.

J Immunol 2017, 198, 2989-2999.

Biased signaling by agonists of protease activated receptor 2.
Jiang Y, Yau MK, Kok WM, Lim J, Wu KC, Liu L, Hill TA, Suen JY, Fairlie DP.

ACS Chem Biol 2017, 12, 1217-1226. 

Mapping transmembrane residues of proteinase activated receptor 2 (PAR2) that influence ligand-modulated calcium signaling.
Suen JY, Adams MN, Lim J, Madala PK, Xu W, Cotterell AJ, He Y, Yau MK, Hooper JD, Fairlie DP.

Pharmacol Research 2017, 117, 328-342. 

Total Synthesis of Mycobacterium tuberculosis Dideoxymycobactin-838 and Stereoisomers: Diverse CD1a-Restricted T Cells Display a Common Hierarchy of Lipopeptide Recognition.
Cheng JM, Liu L, Pellicci DG, Reddiex SJ, Cotton RN, Cheng TY, Young DC, Van Rhijn I, Moody DB, Rossjohn J, Fairlie DP*, Godfrey DI*, Williams SJ*.

Chemistry 2017, 23, 1694-1701.

Stereoelectronic effects on dienophile separation influence the Diels-Alder synthesis of molecular clefts.
Stoermer MJ, Wickramasinghe WA, Byriel KA, Hockless DCR, Skelton BW, Sobolev AN, White AH, Mak JYW, Fairlie DP.

Eur J Org Chem 2017, 6793–6796. 

Downsizing Proto-oncogene cFos to short helix-constrained peptides that bind Jun.
Baxter D, Perry SR, Hill TA, Kok WM, Zaccai NR, Brady RI, Fairlie DP,* Mason JM*

ACS Chem Biol 2017, 12, 2051-2061.

Tolyporphin Macrocycles from the Cyanobacterium Tolypothrix nodosa Selectively Bind Copper and Silver and Reverse Multidrug Resistance.
Prinsep MR, Appleton TG, Hanson GR, Lane I, Smith CD, Puddick J, Fairlie DP.

Inorg Chem 2017, 56, 5577-5585. 

Histone deacetylases (HDAC) in physiological and pathological bone remodelling.
Cantley MD, Zannettino AC, Bartold PM, Fairlie DP, Haynes DR.

Bone 2017, 95, 162-174.

Alpha Helix Nucleation by a Simple Cyclic Tetrapeptide
Hoang HN, Wu C, Beyer RL, Hill TA, Fairlie DP.

Aust J Chem 2017, 70, 213–219.

Mucosal-associated invariant T-cell activation and accumulation after in vivo infection depends on microbial riboflavin synthesis and co-stimulatory signals.
Chen Z, Wang H, D'Souza C, Sun S, Kostenko L, Eckle SB, Meehan BS, Jackson DC, Strugnell RA, Cao H, Wang N, Fairlie DP, Liu L, Godfrey DI, Rossjohn J, McCluskey J, Corbett AJ.

Mucosal Immunol 2017, 10, 58-68.

Receptor residence time trumps drug-likeness and oral bioavailability in determining efficacy of complement C5a antagonists.
Seow V, Lim J, Cotterell AJ, Yau MK, Xu W, Lohman RJ, Kok WM, Stoermer MJ, Sweet MJ, Reid RC, Suen JY, Fairlie DP.

Scientific Reports 20166, 24575. 

Electrophilic helical peptides that bond covalently, irreversibly and selectively in a protein-protein interaction site.
Dantas de Araujo A, Lim J, Good AC, Skerlj RT, Fairlie DP.

ACS Med Chem Lett 2017, 8, 22−26.  [Featured Article] 

An HDAC6 inhibitor confers protection and selectively inhibits B-cell infiltration in DSS-induced colitis in mice.
Do A, Reid RC, Lohman RJ, Sweet MJ, Fairlie DP*, Iyer A*.

J Pharmacol Exp Ther 2017, 360, 140-151. 

Helix-constraints and amino acid substitution in GLP-1 increase cAMP and insulin secretion but not beta arrestin 2 signalling.
Plisson F, Hill TA, Mitchell JM, Hoang HN, de Araujo AD, Xu W, Cotterell A, Edmonds DJ, Stanton RV, Derksen DR, Loria PM, Griffith DA, Price DA, Liras S, Fairlie DP.

Eur J Med Chem 2017, 127, 703-714.

Helix Nucleation by the Smallest Known α-Helix in Water.
Hoang HN, Driver RW, Beyer RL, Hill TA, D de Araujo A, Plisson F, Harrison RS, Goedecke L, Shepherd NE, Fairlie DP.

Angew Chem Int Ed Engl 2016, 55, 8275-8279. 

Downsizing the BAD BH3 peptide to small constrained α-helices with improved ligand efficiency.
Shepherd NE, Harrison RS, Ruiz-Gomez G, Abbenante G, Mason JM, Fairlie DP.

Org Biomol Chem 2016, 14, 10939–10945.

Potent Small Agonists of Protease Activated Receptor 2.
Yau MK, Suen JY, Xu W, Lim J, Liu L, Adams MN, He Y, Hooper JD, Reid RC. and Fairlie DP.

ACS Med Chem Lett 2016, 7, 105-110.

PAR2 modulators derived from GB88
Yau MK, Liu L, Suen JY, Lim J, Lohman R-J, Jiang Y, Cotterel AJ, Barry GD, Mak JYW, Vesey DA, Reid RC. and Fairlie DP.

ACS Med Chem Lett 2016, 7, 1179–1184.

Benzylamide antagonists of protease activated receptor 2 with anti-inflammatory activity.
Yau MK, Liu L, Lim J, Lohman RJ, Cotterell AJ, Suen JY, Vesey DA, Reid RC, Fairlie DP.

Bioorg Chem Med Lett 2016, 26, 986-991.

The intracellular pathway for the presentation of vitamin B-related antigens by the antigen-presenting molecule MR1.
McWilliam HE, Eckle SB1, Theodossis A, Liu L, Chen Z, Wubben J, Fairlie DP, Strugnell RA, Mintern JD, McCluskey J, Rossjohn J, Villadangos JA.

Nature Immunology 2016, 17, 531-537.

A three-stage intrathymic development pathway for the mucosal-associated invariant T cell lineage.
Koay HF, Gherardin NA, Enders A, Loh L, Mackay LK, Almeida CF, Russ BE, Nold-Petry CA, Nold MF, Bedoui S, Chen Z, Corbett AJ, Eckle SB, Meehan B, d'Udekem Y, Konstantinov IE, Lappas M, Liu L, Goodnow CC, Fairlie DP, et al

Nature Immunology 2016, 17, 1300-1311.

Membrane-anchored Serine Protease Matriptase is a Trigger of Pulmonary Fibrogenesis.
Bardou O, Menou A, François C, Duitman JW, von der Thüsen JH, Borie R, Sales KU, Mutze K, Castier Y, Sage E, Liu L, Bugge TH, Fairlie DP, Königshoff M, Crestani B, Borensztajn KS.

Am J Respir Crit Care Med  2016193, 847-860. 


Human mucosal-associated invariant T cells contribute to antiviral influenza immunity via IL-18- dependent activation.
Loha L, Wanga Z, Santa S, Koutsakosa M, Jegaskandaa S, Corbetta AJ, Liu L, Fairlie DP, Crowed J, Rossjohn J, Xuh J, Doherty PC, McCluskey J, Kedzierska K.

Proc Natl Acad Sci 2016, 113, 10133-10138.

Differential Anti-inflammatory Activity of HDAC Inhibitors in Human Macrophages and Rat Arthritis
Lohman R-J, Iyer A, Fairlie TJ, Cotterell A, Gupta P, Reid RC, Vesey DA, Sweet MJ, and Fairlie DP.

J Pharmacol Exp Ther 2016, 356, 387-396.

Antagonism of the proinflammatory and pronociceptive actions of canonical and biased agonists of protease-activated receptor-2.
Lieu T, Savage E, Zhao P, Edgington-Mitchell L, Barlow N, Bron R, Poole DP, McLean P, Lohman RJ, Fairlie DP, Bunnett NW.

Br J Pharmacol 2016, 173, 2752-2765.

Product release is rate-limiting for catalytic processing by Dengue virus protease.
Shannon, AE, Pedroso MM, Chappell KJ, Watterson D, Liebscher S, Kok WM, Fairlie DP, Schenk G, Young PR.

Scientific Reports 20166, 37539; doi: 10.1038/srep37539.

Development of cell-penetrating peptide-based drug leads to inhibit MDMX:p53 and MDM2:p53 interactions.
Philippe G, Huang YH, Cheneval O, Lawrence N, Zhang Z, Fairlie DP, Craik DJ, de Araujo AD, Henriques ST.

Biopolymers 2016, 106(6), 853-863. doi: 10.1002/bip.22893. 

Simultaneous uncoupled expression and purification of the Dengue virus NS3 protease and NS2B co-factor domain.
Shannon AE, Chappell KJ, Stoermer MJ, Chow SY, Kok WM, Fairlie DP, Young PR.

Protein Exp Purif 2016, 119, 124-129.

Truncated glucagon-like peptide-1 and exendin-4 α-conotoxin pl14a peptide chimeras maintain potency, α-helicity and reveal interactions vital for cAMP signaling in vitro.
Swedberg JE, Schroeder CI, Mitchell J, Fairlie DP, Edmonds DJ, Griffith DA, Ruggeri RB, Derksen DR, Loria PM, Price DA, Liras S, Craik DJ.

J Biol Chem 2016, 291, 15778-15787.

Stapling peptides using cysteine crosslinking.
Fairlie DP, de Araujo AD.

Biopolymers 2016, 106(6), 843-852. doi: 10.1002/bip.22877. 

Histone Deacetylase Inhibitors Promote Mitochondrial Reactive Oxygen Species Production and Bacterial Clearance by Human Macrophages
Ariffin JK, Gupta KD, Kapetanovic R, Iyer A, Reid RC, Fairlie DP. and Sweet MJ.

Antimicrobial Agents and Chemotherapy 2016, 60, 1521-1529.

Diversity of T Cells Restricted by the MHC Class I-Related Molecule MR1 Facilitates Differential Antigen Recognition
Gherardin NA, Keller AN, Woolley RE, Le Nours J, Ritchie DS, Neeson PJ, Birkinshaw RW, Eckle SBG, Waddington JN, Liu L, Fairlie DP, Uldrich AP, Pellicci DG, McCluskey J, Godfrey DI, Rossjohn J.

Immunity 201644, 32-45. [ISI Highly Cited]

Protease activated receptor 2 (PAR2) modulators: a patent review (2010-2015)
Yau M-K, Lim J, Liu L. & Fairlie DP.

Expert Opinion on Therapeutic Patents 2016, 471-483.

Histone deacetylases in monocyte/macrophage development, activation and metabolism: refining HDAC targets for inflammatory and infectious diseases
Gupta KD, Shakespear MR, Iyer A, Fairlie DP. and Sweet MJ.

Clinical and Translational Immunology 2016, 5, e62.

Nutrient and immune sensing are obligate pathways in metabolism, immunity, and disease.
Iyer A, Brown L, Whitehead JP, Prins JB, Fairlie DP.

FASEB J 2015, 29, 3612-3625.

Short hydrophobic peptides with cyclic constraints are potent glucagon-like peptide-1 receptor (GLP-1R) agonists.
Hoang HN, Song K, Hill TA, Derksen DR, Edmonds DJ, Kok WM, Limberakis C, Liras S, Loria PM, Mascitti V, Mathiowetz AM, Mitchell JM, Piotrowski DW, Price DA, Stanton RV, Suen JY, Withka JM, Griffith DA, Fairlie DP.

J Med Chem 2015, 58, 4080-4085.

Flexibility versus Rigidity for Orally Bioavailable Cyclic Hexapeptides
Nielsen DS, Lohman RJ, Hoang HN, Hill TA, Jones A, Lucke AJ, Fairlie DP.

ChemBioChem 2015, 16, 2289-2293.

Identification of phenotypically and functionally heterogeneous mouse mucosal-associated invariant T cells using MR1 tetramers
Rahimpour A, Koay HF, Enders A, Clanchy R, Eckle SBG, Meehan B, Chen Z, Whittle B, Liu L, Fairlie DP, Goodnow CC, McCluskey J, Rossjohn J, Uldrich AP, Pellicci DG. and Godfrey DI.

J Exp Med 2015, 212, 1095-1108.

Small Molecule Inhibitors of Disulfide Bond Formation by the Bacterial DsbA-DsbB Dual Enzyme System.
Halili MA, Bachu P, Lindahl F, Bechara C, Mohanty B, Reid RC, Scanlon MJ, Robinson CV, Fairlie DP, Martin JL.

ACS Chem Biol 2015, 10, 957–964.

Helix-Constrained Nociceptin Peptides Are Potent Agonists and Antagonists of ORL-1 and Nociception, in Nociceptin Opioid.
Lohman RJ, Harrison RS, Ruiz-Gómez GG, Hoang HN, Shepherd NE, Chow S, Hill TA, Madala PK, Fairlie DP.

Vitamins and Hormones 2015, 97, 1–55.

Functional Heterogeneity and Antimycobacterial Effects of Mouse Mucosal-Associated Invariant T Cells Specific for Riboflavin Metabolites.
Sakala IG, Kjer-Nielsen L, Eickhoff CS, Wang X, Blazevic A, Liu L, Fairlie DP,Rossjohn J, McCluskey J, Fremont DH, Hansen TH, Hoft DF.

J Immunol 2015, 195, 587-601.

Downsizing Proteins Without Losing Potency or Function
Fairlie DP, Yau MK, Hamidon JK, Singh R, Lim J, Suen JY, Rowley JA, Lohman RJ, Stoermer MJ, Iyer A, Reid RC.

Proc 24th Amer Peptide Symp (June 2015); Srivastava V, Yudin A, Lebl M (Eds); American Peptide Society 2015, 16-19. http://dx.doi.org/10.17952/24APS.2015.016

Potent complement C3a receptor agonists derived from oxazole amino acids: Structure-activity relationships.
Singh R, Reed AN, Chu P, Scully CC, Yau MK, Suen JY, Durek T, Reid RC, Fairlie DP.

Bioorg Med Chem Lett 2015, 25, 5604-5608. 

Recognition of Vitamin B precursors and byproducts by Mucosal Associated Invariant T cells.
Eckle SB, Corbett AJ, Keller A, Chen Z, Godfrey DI, Liu L, Mak JY, Fairlie DP, Rossjohn J, McCluskey J.

J Biol Chem 2015, 290, 30204-30211. 

Cyclic alpha-conotoxin peptidomimetic chimeras as potent GLP-1R agonists.
Swedberg JE, Schroeder CI, Mitchell JM, Durek T, Fairlie DP, Edmonds DJ, Griffith DA, Ruggeri RB, Derksen DR, Loria PM, Liras S, Price DA, Craik DJ.

Eur J Med Chem 2015, 103, 175-184. 

Thiazoles in Peptides and Peptidomimetics
Mak JYW, Xu W, Fairlie DP

Topics in Heterocyclic Chemistry: “Heterocyclic Peptidomimetics” Chapter 1, 2015, 1-32. DOI: 10.1007/7081_2015_176.

Towards peptide-based inhibitors as therapies for Parkinson's disease
Mason JM, Fairlie DP

Future Medicinal Chemistry 2015, 7, 2103-2105.

Comparing Sixteen Scoring Functions for Predicting Biological Activities of Ligands for Protein Targets.
Xu W, Lucke AJ, Fairlie DP.

J Mol Graphics Modelling 2015, 57, 76-88.

Three homology models of PAR2 derived from different templates: application to antagonist discovery.
Perry SR, Xu W, Wirija A, Lim J, Yau MK, Stoermer MJ, Lucke AJ, Fairlie DP.

J Chem Info Model 2015, 55, 1181−1191.

Inhibiting Histone Deacetylase 1 (HDAC 1) Suppresses both Inflammation and Bone Loss in Arthritis.
Cantley MD, Fairlie DP, Bartold PM, Marino V, Gupta PK, Haynes DR.

Rheumatology 2015, 54, 1713-1723.

Peptide Inhibitors of the Escherichia coli DsbA Oxidative Machinery Essential for Bacterial Virulence.
Duprez W, Premkumar L, Halili MA, Lindahl F, Reid RC, Fairlie DP, Martin JL.

J Med Chem 2015, 58, 577-587.

Facile synthesis of mono- and bis-methylated Fmoc-Dap, -Dab and -Orn amino acids
Lindahl F, Hoang HN, Fairlie DP, Cooper MA.

Chem Commun  2015, 51, 4496-4498.

Virtual Screening of Peptide and Peptidomimetic Fragments Targeted to Inhibit Bacterial Dithiol Oxidase DsbA.
Duprez W, Bachu P, Stoermer MJ, Tay S, McMahon RM, Fairlie DP, Martin JL.

PLoS One 2015, 10(7), e0133805.

 


Profiling the anti-protozoal activity of anti-cancer HDAC inhibitors against Plasmodium and Trypanosoma parasites
Engel JA, Jones AJ, Avery VM, Sumanadasa SD, Ng SS, Fairlie DP, Adams TS, Andrews KT.

Int J Parasitol Drugs: Drug Resist 2015, 5, 117-126.

T cell activation by transitory neo-antigens derived from distinct microbial pathways.
Corbett AJ, Eckle SBG, Birkinshaw RW, Liu L, Patel O, Mahony J, Chen Z, Reantra-goon R, Meehan B, Cao H, Williamson NA, Strugnell RA, Sinderen DV, Mak JYW, Fairlie DP*, Lars Kjer-Nielsen*, Rossjohn J*, McCluskey J*.

Nature 2014, 509, 361-365. [ISI: Highly Cited Article]

Constraining Cyclic Peptides To Mimic Protein Structure Motifs.
Hill TA, Shepherd NE, Diness F, Fairlie DP.

Angew Chem Int Edit 2014, 53, 13020-13041.

Improving on Nature: Making a Cyclic Heptapeptide Orally Bioavailable.
Nielsen DS, Hoang HN, Lohman RJ, Hill TA, Lucke AJ, Craik DJ, Edmonds DJ, Griffith DA, Rotter CJ, Ruggeri RB, Price DA, Liras S, Fairlie DP.

Angew Chem Int Edit 2014, 53, 12059-12063.

 

Comparative α-Helicity of Cyclic Pentapeptides in Water.
de Araujo AD, Hoang HN, Kok WM, Diness F, Gupta G, Hill TA, Driver RW, Price DA, Liras S, Fairlie DP.

Angew Chem Int Edit 2014, 53, 6965-6969.

Stereoelectronic effects dictate molecular conformation and biological function of heterocyclic amides.
Reid RC, Yau MK; Singh R, Lim J, Fairlie DP.

J Am Chem Soc 2014, 136, 11914-11917. [Faculty1000Prime recommendation] 

Rational design and synthesis of an orally bioavailable peptide guided by NMR amide temperature coefficients.
Wang CK, Northfield SE, Colless B, Chaousis D, Hamernig I, Lohman RJ, Nielsen DS, Schroeder CI, Liras S, Price DA, Fairlie DP, Craik DJ.

Proc Natl Acad Sci 2014, 111, 17504-17509.

A Molecular Basis Underpinning the T Cell Heterogeneity of Mucosal Associated Invariant T Cells.
Eckle SBG, Birkinshaw RW, Kostenko L, Corbett AJ, McWilliam HEG, Reantragoon R, Chen Z, Gherardin NA, Beddoe T, Liu L, Patel O, Meehan B, Fairlie DP, Villadangos JA, Godfrey DI, Kjer-Nielsen L, McCluskey J, Rossjohn J.

J Exp Med 2014, 211, 1585-1600.

Cyclic Penta- and Hexa- Leucine Peptides Without N-Methylation Are Orally Absorbed.
Hill T, Lohman RJ, Hoang HN, Nielsen DS, Scully CCG, Kok WM, Liu L, Lucke AJ, Stoermer MJ, Schroeder CI, Chaousis S, Colless B, Bernhardt PV, Edmonds DJ, Griffith DA, Rotter CJ, Ruggeri RB, Price DA, Liras S, Craik DJ, Fairlie DP.

ACS Med Chem Lett 2014, 5, 1148–1151. [Faculty1000Prime recommendation] 

Potent Heterocyclic Ligands for Human Complement C3a Receptor.
Reid RC, Yau M-K, Singh R, Hamidon JK, Lim J, Stoermer MJ, Fairlie DP.

J Med Chem 2014, 57, 8459−8470.

Complement C5a receptor facilitates cancer metastasis by altering T cell responses in the metastatic niche
Vadrevu SK, Chintala NK, Sharma SK, Sharma P, Cleveland C, Riediger L, Manne S, Fairlie DP, Gorczyca W, Almanza O, Karbowniczek M, Markiewski MM

Cancer Research 2014, 74, 3454-3465.

Pathway Selective Antagonism Of Proteinase Activated Receptor 2.
Suen JY, Cotterell A, Lohman RJ, Lim J, Han A, Yau MK, Liu L, Cooper MA, Vesey DA, Fairlie DP.

Br J Pharmacol 2014, 171, 4112-4124.

Biased Signalling and Proteinase-Activated Receptors (PARs): Targeting Inflammatory Disease.
Hollenberg MD, Mihara K, Polley D, Suen JY, Han A, Fairlie DP, Ramachandran R.

Br J Pharmacol 2014,  171, 1180-1194. [ISI Highly Cited]

Crystal Structure of the Dithiol Oxidase DsbA Enzyme from Proteus Mirabilis Bound Non-Covalently to an Active Site Peptide Ligand.
Kurth F, Duprez W, Premkumar L, Schembri M, Fairlie DP, Martin JL.

J Biol Chem 2014, 289, 19810-19822.

Helical cyclic pentapeptides constrain HIV-1 Rev peptide for enhanced RNA binding.
Harrison RS, Shepherd NE, Hoang HN, Beyer RL, Ruiz-Gómez G, Kelso MJ, WM Kok, TA Hill, Abbenante G, Fairlie DP.

Tetrahedron 2014, 70, 7645-7650.

Lysine acetylation in sexual stage malaria parasites is a target for antimalarial small molecules.
Trenholme K, Marek L, Duffy S, Pradel G, Fisher G, Hansen FK, Skinner-Adams TS, Butterworth A, Julius Ngwa C, Moecking J, Goodman CD, McFadden GI, Sumanadasa SD, Fairlie DP, Avery VM, Kurz T, Andrews KT.

Antimicrob Agents Chemother 2014, 58, 3666-3678.

C5aR and C5L2 act in concert to balance immunometabolism in adipose tissue.
Poursharifi P, Lapointe M, Fisette A, Lu H, Roy C, Munkonda MN, Fairlie DP, Cianflone K.

Molecular and Cellular Endocrinology 2014, 382, 325-333.

C5aR and C3aR antagonists each inhibit diet-induced obesity, metabolic dysfunction, and adipocyte and macrophage signaling.
Lim J, Iyer A, Suen JY, Seow V, Reid RC, Brown L, Fairlie DP.

FASEB J 2013, 27, 822-831.

Diet-induced obesity, adipose inflammation, and metabolic dysfunction correlating with PAR2 expression are attenuated by PAR2 antagonism.
Lim J, Iyer A, Liu L, Suen JY, Lohman RJ, Seow V, Yau MK, Brown L, Fairlie DP.

FASEB J 2013, 27, 4757-4767.

Downsizing a Human Inflammatory Protein to a Small Molecule with Equal Potency and Functionality.
Reid RC, Yau M-K, Singh R, Hamidon JK, Reed AN, Chu P, Suen JY, Stoermer MJ, Blakeney JS, Lim J, Faber JM, Fairlie DP.

Nature Communications 2013, 4, 2802. doi: 10.1038/ncomms3802.

The Future of Peptide-Based Drugs.
David J. Craik, David P. Fairlie, Spiros Liras and David Price.

Chem Biol Drug Des 2013, 81, 136-147. [ISI Highly Cited] [ISI Hot Paper]

Inflammatory responses induced by lipopolysaccharide are amplified in primary human monocytes but suppressed in macrophages by complement protein C5a.
Seow V, Lim J, Iyer A, Suen JY, Ariffin JK, Hohenhaus DM, Sweet MJ, Fairlie DP.

J Immunol 2013, 191, 4308-4316.

Towards Drugs for Protease-Activated Receptor 2 (PAR2).
Yau MK, Liu L, Fairlie DP.

J Med Chem 2013, 56, 7477–7497.

Histone deacetylase 7 promotes Toll-like Receptor 4-dependent pro-inflammatory gene expression in macrophages.
Shakespear MR, Hohenhaus DM, Kelly GM, Kamal NA, Gupta P, Labzin LI, Schroder K, Garceau V, Barbero S, Iyer A, Hume DA, Reid RC, Irvine KM, Fairlie DP, Sweet MJ.

J Biol Chem 2013288, 25362-25374.

Antigen-loaded MR1 tetramers define T cell receptor heterogeneity in Mucosal-Associated Invariant T-cells.
Reantragoon R, Corbett AJ, Sakala IG, Gherardin NA, Furness JB, Birkinshaw R, Chen Z, Patel O, Kostenko L, Meehan B, Eckle SBG, Kedzierska K, Pellicci D, Liu L, Fairlie DP, Godfrey DI, Hansen TH, Kjer-Nielsen L, Rossjohn J, McCluskey J.

J Exp Med 2013, 210, 2305-2320. [ISI Highly Cited]

Recognition of vitamin B metabolites by mucosal-associated invariant T cells.
Patel O, Kjer-Nielsen L, Nours JL, Eckle SBG, Bikinshaw R, Beddoe T, Corbett AJ, Liu L, Miles JJ, Mehan B, Reantragoon R, Sandoval-Romero ML, Sullivan LC, Brooks AG, Chen Z, Fairlie DP, McCluskey J, Rossjohn J.

Nature Commun 2013, 4, 2142. doi: 10.1038/ncomms3142.

Efficient chemical synthesis of human complement protein C3a.
Artin Ghassemian,zy Ching-I Anderson Wang,y Mei-Kwan Yau, Robert C. Reid, Richard J. Lewis, David P. Fairlie, Paul F. Alewood and Thomas Durek.

Chem Commun 2013, 49, 2356-2358.

Rv2969c, essential for optimal growth in Mycobacterium tuberculosis, is a DsbA-like enzyme that interacts with VKOR-derived peptides and has atypical features of DsbA-like disulfide oxidases.
Premkumar L, Heras B, Duprez W, Walden P, Halili M, Kurth F, Fairlie DP, Martin JL.

Acta Crystallogr D Biol Crystallogr 2013D69, 1981–1994.

An interaction between the methyltransferase and RNA dependent RNA polymerase domains of the West Nile virus NS5 protein.
Tan CS, Hobson-Peters JM, Stoermer MJ, Fairlie DP, Khromykh AA, Hall RA.

J Gen Virol 2013, 94, 1961-1971. 

Truncated and helix-constrained peptides with high affinity and specificity for the cFos coiled-coil of AP-1.
Rao T, Ruiz-Gómez G, Hill TA, Hoang HN, Fairlie DP, Mason JM.

PLoS One 2013, 8(3), e59415.

Identification and characterization of bi-thiazole-2,2′-diamines as kinase inhibitory scaffolds.
Kevin R.W. Ngoei, Dominic C.H. Ng, Paul R. Gooley, David P. Fairlie, Martin J. Stoermer, Marie A. Bogoyevitch.

Biochimica et Biophysica Acta, 2013, 1834, 1077-1088.

C5a, but not C5a-des Arg, induces upregulation of heteromer formation between complement C5a receptors C5aR and C5L2.
Croker DE, Halai R, Fairlie DP, Cooper MA.

Immunol Cell Biol. 2013, 91, 625-633. 

The α-Proteobacteria Wolbachia pipientis Protein Disulfide Machinery Has a Regulatory Mechanism Absent in γ-Proteobacteria
Walden PM, Halili MA, Archbold JK, Lindahl F, Fairlie DP, Inaba K, Martin JL

PLOS One  20138 (11), e81440.

PAR2-induced inflammatory responses in human kidney tubular epithelial cells.
David A. Vesey, Jacky Y. Suen, Vernon Seow, Rink-Jan Lohman, Ligong Liu, Glenda C. Gobe, David W. Johnson, and David P. Fairlie.

Am J Physiol Renal Physiol, 2013, 304, F737-F750.

MR1 presents microbial vitamin B metabolites to MAIT cells.
Kjer-Nielsen L, Patel O, Nours JL, Meehan B, Corbett AJ, Liu L, Bhati M, Chen Z, Kostenko L, Reantragoon R, Williamson NA, Purcell AW, Dudek NL, McConville MJ, O’Hair RAJ, Khairallah GN, Godfrey DI, Fairlie DP, Rossjohn J, McCluskey J.

Nature 2012, 491, 717-723. [Faculty1000Prime recommendation] [ISI Highly Cited]

Catalyst-Free N-arylation Using Unactivated Fluorobenzenes.
Diness F, Fairlie DP.

Angew. Chem. Int. Edit. 201251, 8012-8016.

Total Synthesis, Structure, and Oral Absorption of a Thiazole Cyclic Peptide, Sanguinamide A.
Nielsen DS, Hoang HN, Lohman RJ, Diness F, Fairlie DP.

Org Lett. 2012, 14, 5720–5723.

An antagonist of human protease activated receptor-2 attenuates PAR2 signaling, macrophage activation, mast cell degranulation, and collagen-induced arthritis in rats.
Lohman RJ, Cotterell AJ, Barry GD, Liu L, Suen JY, Vesey DA, Fairlie DP.

FASEB J. 2012, 26, 2877-2887.

An inhibitor of pla2g2a modulates adipocyte signaling and protects against diet-induced metabolic syndrome in rats.
Iyer A, Lim J, Poudyal H, Reid RC, Suen JY, Webster J, Prins JB, Whitehead JP, Fairlie DP*, Brown L*.

Diabetes 2012, 61(9), 2320-2329.

Towards Histone Deacetylase Inhibitors as New Antimalarial Drugs.
Andrews KT, Tran TN, Fairlie DP.

Current Pharmaceutical Design 201218, 3467-79.

Antagonism of protease activated receptor 2 protects against experimental colitis.
Lohman RJ, Cotterell AJ, Suen JY, Liu L, Do TA, Vesey DA, Fairlie DP.

J Pharmacol Exp Ther. 2012, 340, 256-265.

Modulating Human Proteinase Activated Receptor 2 With A Novel Antagonist (GB88) and Agonist (GB110)
Suen JY, Barry GD, Lohman RJ, Halili MA, Cotterell AJ, Le GT, Fairlie DP.

Br J Pharmacol. 2012, 165, 1413-1423.

Targeting quorum sensing and competence stimulation for antimicrobial chemotherapy.
Shepherd NE, Harrison RS, Fairlie DP.

Current Drug Targets 2012, 13(11), 1348-1359. 

Anti-malarial activity of the anti-cancer HDAC inhibitor SB939.
Sumanadasa SD, Goodman CD, Lucke AJ, Skinner-Adams T, Sahama I, Haque A, Do TA, McFadden GI, Fairlie DP, Andrews KT.

Antimicrob Agents Chemother. 2012, 56, 3849-3856. 

Matching cavities in G protein-coupled receptors to infer ligand-binding sites.
Madala PK, Fairlie DP, Boden M.

J. Chem. Inf. Model. 201252, 1401-1410.

Comparative Gene Expression Profiling of P. falciparum Malaria Parasites Exposed to Three Different Histone Deacetylase Inhibitors.
Andrews KT, Gupta AP, Tran TN, Fairlie DP, Gobert GN, Bozdech Z.

PLoS One, 2012, 7, e31847

Folding pentapeptides into left and right handed alpha helices
Hoang, HN, Abbenante G, Hill TA, Ruiz-Gomez G, Fairlie DP

Tetrahedron, 2012,  68, 4513–4516.

C5a Receptor (CD88) Inhibition Improves Hypothermia-induced Neuroprotection in an In Vitro Ischemic Model
Thundyil J, Pavlovski D, Hsieh YH, Gelderblom M, Magnus T, Fairlie DP, Arumugam, TV.

Neuromolecular Med. 2012, 14, 30-39.

HDACs and their Inhibitors in Immunology: Teaching Anticancer Drugs New Tricks.
Fairlie DP, Sweet MJ.

Immunol Cell Biol, 2012, 90, 3-5.

Lysine Acetylation in Obesity, Diabetes and Metabolic Disease.
Iyer A, Fairlie DP, Brown L.

Immunol Cell Biol. 2012, 90, 39-46.

HDAC inhibitors: modulating leukocyte differentiation, survival, proliferation and inflammation.
Sweet MJ, Shakespear MR, Kamal NA, Fairlie DP.

Immunol Cell Biol. 2012, 90, 14-22.

Structures of Peptide Agonists for Human Protease Activated Receptor 2
Stoermer MJ, Flanagan B, Beyer RL , Madala PK, Fairlie DP.

Bioorg. Med. Chem. Lett. 2012, 22, 916-919.

Ful Text via ScienceDirect

Chemical Biology Down Under.
Fairlie DP.

Current Topics in Medicinal Chemistry 2012, 12(14), 1469-1470.

Towards Isozyme-Selective HDAC Inhibitors For Interrogating Disease.
Gupta P, Reid RC, Iyer A, Sweet MJ, Fairlie DP.

Current Topics in Medicinal Chemistry 2012, 12(14), 1479-1499.

Histone deacetylase inhibitors as suppressors of bone destruction in inflammatory diseases.
Cantley MD, Bartold PM, Fairlie DP, Rainsford KD, Haynes DR.

J. Pharm. Pharmacol. 2012, 64, 763-774.

Protein α-Turns Recreated in Structurally Stable Small Molecules.
Hoang HN, Driver RW, Beyer RL, Malde AK, Le GT, Abbenante G, Mark AE, Fairlie DP.

Angew. Chem. Int. Ed. Engl. 2011, 50, 11107-11111.

Synthesis of the Thiazole-Thiazoline Fragment of Largazole Analogues.
Diness F, Nielsen DS, Fairlie DP.

J. Org. Chem. 2011, 76, 9845-9851.

Inhibitors of Histone Deacetylases in Class I and Class II Suppress Human Osteoclasts In Vitro
Cantley MD, Fairlie DP, Bartold PM, Rainsford KD, Le GT, Lucke AJ, Holding CA, Haynes DR

J. Cellular Physiology, 2011226, 3233-3241.

Ex Vivo Activity of Histone Deacetylase Inhibitors against Multidrug-Resistant Clinical Isolates of Plasmodium falciparum and P. vivax.
Marfurt J, Chalfein F, Prayoga P, Wabiser F, Kenangalem E, Piera KA, Fairlie DP, Tjitra E, Anstey NM, Andrews KT, Price RN.

Antimicrob Agents Chemother. 201155, 961-966.

Histone deacetylase inhibitors and periodontal bone loss
Cantley MD, Bartold PM, Marino V, Fairlie DP, Le GT, Lucke AJ, Haynes DR.

Journal of Periodontal Research 2011, 46, 697–703.

Structure, function and pathophysiology of protease activated receptors.
Adams MN, Ramachandran R, Yau MK, Suen JY, Fairlie DP, Hollenberg MD, Hooper JD.

Pharmacol Ther 2011, 130, 248-282. [ISI Highly Cited]

Amyloid Formation from an α-Helix Peptide Bundle Is Seeded by 310-Helix Aggregates.
Singh Y, Sharpe PC, Hoang HN, Lucke AJ, McDowall AW, Bottomley SP, Fairlie DP.

Chemistry Eur. J.  2011, 17, 151-160. ["Very Important Paper" Category]

Inflammatory lipid mediators in adipocyte function and obesity.
Abishek Iyer, David P. Fairlie, Johannes B. Prins, Bruce D. Hammock and Lindsay Brown.

Nature Reviews Endocrinology 2010, 6, 71-82. 

Downsizing human, bacterial, and viral proteins to short water-stable alpha helices that maintain biological potency.
Harrison RS, Shepherd NE, Hoang HN, Ruiz-Gomez G, Hill TA, Driver RW, Desai VS, Young PR, Abbenante G, Fairlie DP.

Proc. Natl. Acad. Sci 2010, 107, 11686-11691.

Novel Helix-Constrained Nociceptin Derivates Are Potent Agonists and Antagonists of ERK Phosphorylation and Thermal Analgesia in Mice.
Harrison RS, Ruiz-Gómez G, Hill TA, Chow SY, Shepherd NE, Lohman R-J, Abbenante G, Hoang HN, Fairlie DP.

J. Med. Chem. 2010, 53, 8400–8408.

Novel Agonists and Antagonists for Human Protease Activated Receptor 2 (PAR2).
Barry GD, Suen JY, Le GT, Cotterell A, Reid RC, Fairlie DP.

J. Med. Chem. 2010, 53, 7428-7440.

Non-covalent tripeptidylbenzyl and cyclohexyl amine inhibitors of the cysteine protease caspase-1.
Löser R, Abbenante G, Madala PK, Halili M, Le GT, Fairlie DP.

J. Med. Chem. 2010, 53, 2651-2655.

Selective Hexapeptide Agonists and Antagonists for Human Complement C3a Receptor.
Scully CCG, Blakeney JS, Singh R, Hoang, HN, Abbenante G, Reid RC, Fairlie DP.

J. Med. Chem. 2010, 53, 4938-4948.

Inhibitors Selective For HDAC6 In Enzymes and Cells.
Gupta PK, Reid RC, Liu L, Lucke AJ, Broomfield SA, Andrews MR, Sweet MJ, Fairlie DP.

Bioorg. Med. Chem. Lett. 2010, 20, 7067-7070.

Antimalarial Histone Deacetylase Inhibitors Containing Cinnamate or NSAID Components.
Wheatley NC, Andrews KT, Tran TL, Lucke AJ, Reid RC, Fairlie DP.

Bioorg. Med. Chem. Lett. 2010, 20, 7080-7084.

Update 1 of: Over One Hundred Peptide-Activated G Protein-Coupled Receptors Recognize Ligands with Turn Structure.
Gloria Ruiz-Gómez, Joel D. A. Tyndall, Bernhard Pfeiffer, Giovanni Abbenante and David P. Fairlie.

Chemical Reviews, 2010, 110(4), PR1-PR41.

Update 1 of: Beta-Strand Mimetics.
Loughlin WA, Tyndall JD, Glenn MP, Hill TA, Fairlie DP.

Chemical Reviews 2010, 110(6), PR32-PR69.

Update 1 of: Proteases Universally Recognize Beta Strands in their active sites.
Madala PK, Tyndall JD, Nall T, Fairlie DP.

Chemical Reviews 2010, 110(6), PR1-PR31.

Profiling gene expression induced by protease-activated receptor 2 (PAR2) activation in human kidney cells.
Suen JY, Gardiner B, Grimmond S, Fairlie DP.

PLoS One 2010, 5, e13809.

Differential effects of selective HDAC inhibitors on macrophage inflammatory responses to the Toll-like receptor 4 agonist LPS.
Halili MA, Andrews MR, Labzin LI, Schroder K, Matthias G, Cao C, Lovelace E, Reid RC, Le GT, Hume DA, Irvine KM, Mathias P, Fairlie DP, Sweet MJ.

J Leukoc Biol. 2010, 87, 1103-1114.

Antifibrotic activity of an inhibitor of histone deacetylases in DOCA-salt hypertensive rats.
Iyer A, Fenning A, Lim J, Le GT, Reid RC, Halili MA, Fairlie DP, Brown L.

Br J Pharmacol. 2010, 159, 1408-1417.